Search

The interaction of von Willebrand factor with platelet glycoprotein Ib: pathological implications and clinical manifestations

The EHA Specialized Working Group (SWG) on Thrombocytopenias and Platelet Function Disorders and the EHA-SWG on Bleeding and Thrombosis are pleased to collaborate on a recent free webinar: "The interaction of von Willebrand factor with platelet glycoprotein Ib: pathological implications and clinical…

Read more

Position of EHA on Research Funding

 

The challenge
The cost of biomedical research is great, but the cost of disease is immense. An ageing population and expensive innovations in medicine put an increasing burden on already stressed healthcare budgets.

Read more

EHA-funded study in The Lancet Haematology: Economic Burden of Blood Disorders in EU is €23 billion

In Europe blood disorders affect around 80 million people. The total cost of blood disorders consists of healthcare expenditure (€15. 6 billion), productivity loss due to illness and mortality (€5. 6 billion), and the costs of informal care (€1.

Read more

Corporate Sponsor Program

EHA Ranking for 2024 is now accessible via this link. "Alone we can do so little; together we can do so much.

Read more

Shining a Light on Blood Cancer

EHA Launches Digital Campaign

In September 2021, the European Hematology Association (EHA) will honor Blood Cancer Awareness Month with an extensive digital campaign.

Read more

Senior Project Manager Research Grants

Our Company

The European Hematology Association (EHA) is a non-profit organization located in The Hague which serves medical professionals, researchers, and scientists with an active interest in hematology.

Read more

Project Manager Medical Education

Our Company

The European Hematology Association (EHA) is a non-profit organization located in The Hague which serves medical professionals, researchers, and scientists with an active interest in hematology.

Read more